Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).

This is written in the approval document.

Reimbursement

ODMS

Citation

Brentuximab vedotin Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-12-01	Health Service Executive	Indication approved for reimbursement.